Books on the topic 'Aminoglycoside antibiotics'

To see the other types of publications on this topic, follow the link: Aminoglycoside antibiotics.

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 18 books for your research on the topic 'Aminoglycoside antibiotics.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Arya, D. P. Aminoglycoside antibiotics: From chemical biology to drug discovery. Hoboken, N.J: Wiley-Interscience, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Lazenby, Charles Mark. The effect of aminoglycoside antibiotics on erythrocyte membrane potassium ion transport. Birmingham: Aston University. Department of Pharmaceutical Sciences, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Umezawa, Hamao, and Irving R. Hooper. Aminoglycoside Antibiotics. Brand: Springer, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Arya, Dev P., ed. Aminoglycoside Antibiotics. Wiley, 2007. http://dx.doi.org/10.1002/9780470149676.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Koeda, T., Y. Ito, Hamao Umezawa, and Irving R. Hooper. Aminoglycoside Antibiotics. Springer London, Limited, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Barnes, William G., and Glenn R. Hodges. Aminoglycoside Antibiotics a Guide to Therapy. Taylor & Francis Group, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Barnes, William G., and Glenn R. Hodges. Aminoglycoside Antibiotics a Guide to Therapy. Taylor & Francis Group, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Barnes, William G., and Glenn R. Hodges. Aminoglycoside Antibiotics a Guide to Therapy. Taylor & Francis Group, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Barnes, William G., and Glenn R. Hodges. Aminoglycoside Antibiotics: A Guide to Therapy. Taylor & Francis Group, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Barnes, William G., and Glenn R. Hodges. Aminoglycoside Antibiotics a Guide to Therapy. Taylor & Francis Group, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
11

Barnes, William G., and Glenn R. Hodges, eds. The Aminoglycoside Antibiotics: A Guide To Therapy. CRC Press, 2019. http://dx.doi.org/10.1201/9780429280184.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Arya, Dev P. Aminoglycoside Antibiotics: From Chemical Biology to Drug Discovery. Wiley & Sons, Incorporated, John, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
13

Schroeder, Renee, and Mary G. Wallis. RNA-Binding Antibiotics (American Rustic). Landes Bioscience, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
14

Herald, Patricia Ann. RELATIONSHIP BETWEEN HYDRATION STATUS AND RENAL FUNCTION IN PATIENTS RECEIVING AMINOGLYCOSIDE ANTIBIOTICS. 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
15

Rusnak, Donald E. Establishment of a pharmacokinetic monitoring service for aminoglycoside antibiotics at National Defence Medical Centre. 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
16

Arya, Dev P. Aminoglycoside Antibiotics: From Chemical Biology to Drug Discovery (Wiley Series in Drug Discovery and Development). Wiley-Interscience, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
17

Gilchrist, Francis J., and Alex Horsley. Management of respiratory exacerbations. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780198702948.003.0005.

Full text
Abstract:
Cystic fibrosis lung disease is characterized by chronic infection, inflammation and a progressive loss of lung function. Patients are also affected by recurrent episodes of increased respiratory symptoms, called exacerbations which have a detrimental effect on quality of life, the rate of lung function decline, and mortality. Early diagnosis and treatment is vital. Diagnosis relies on a combination of symptoms, examination findings, the results of laboratory tests, and lung function. Antibiotics are the mainstay of treatment but airway clearance, nutrition, and glucose homeostasis must also be optimized. Mild exacerbations are usually treated with oral antibiotics and more severe exacerbations with intravenous antibiotics. The choice of antibiotic is guided by the patient’s chronic pulmonary infections, the in-vitro antibiotic sensitivities, known antibiotic allergies, and the previous response to treatment. In patients with chronic Pseudomonas aeruginosa infection, antibiotic monotherapy is thought to increase the risk of resistance and treatment with 2 antibiotics is therefore suggested (usually a β‎-lactam and an aminoglycoside). Although there is a lack of evidence on the duration of treatment, most patients receive around 14 days. This can be altered according to the time taken for symptoms and lung function to return to pre-exacerbation levels. If patients are carefully selected and receive appropriate monitoring, home intravenous antibiotics can be as effective as in-patient treatment. They are also associated with decreased disruption to patients / family life, decreased risk of cross infection and decreased costs.
APA, Harvard, Vancouver, ISO, and other styles
18

Goffin, Eric, Laura Labriola, and Michel Jadoul. Bacterial and fungal infections in patients on peritoneal dialysis. Edited by Jonathan Himmelfarb. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0270.

Full text
Abstract:
Infections specifically related to peritoneal dialysis include peritonitis on the one hand, and exit-site and tunnel infections on the other hand.The diagnosis of peritonitis rests on the classical triad of cloudy dialysate, abdominal pain, and presence of < 100 white-cells (including < 50 % polymorphonuclear cells) within the dialysate effluent. Because peritonitis is associated with high mortality and morbidity rates, empiric antibiotics should be initiated without delay, covering both Gram-positive and Gram-negative organisms. Most regimens include vancomycin or a first-generation cephalosporin for the former, and a third-generation cephalosporin or an aminoglycoside for the latter. Antibiotics are usually administered via the intraperitoneal route. Prophylaxis with an anti-fungal agent has to be considered in diabetic patients and in those who just received prolonged antibiotic administration. Cure is obtained in up to 80 % of the cases ; treatment failure however may occur with refractory or relapsing peritonitis episodes. This is especially common in fungal or fecal associated peritonitis, and will require catheter withdrawal. The incidence of peritonitis has dramatically decreased in recent years with the advent of new connectology systems, and both adequate preventive measures and improved patients’ education. Still it is not clearly documented that new biocompatible dialysate fluids have a favorable effect on peritonitis incidence.Exit-site and tunnel infections are defined by the presence of a purulent discharge around the catheter and by erythema, oedema and tenderness of the subcutaneous pathway of the catheter, respectively. Antibiotics are recommended in case of documented infection. Cuff shaving may sometimes be required, as well as catheter removal in case of unfavourable evolution.
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography